Q1 · MEDICINE
Article
Author: D'Alessandro, Angelo ; Protopapa, Pantelitsa ; Gribben, John G ; Kubasch, Anne Sophie ; Philippe, Céline ; Piganeau, Marion ; Bianchi, Katiuscia ; Bergot, Tiffany ; Wang, Jun ; Gallipoli, Paolo ; Platzbecker, Uwe ; Wiseman, Daniel H ; Kordasti, Shahram ; Bonnet, Dominique ; Mian, Syed A ; Rouault-Pierre, Kevin ; Cross, Michael ; Di Bella, Doriana ; Morales, Valle ; Finch, Andrew J ; Maniati, Eleni ; Nemkov, Travis ; Bernard, Delphine G
Patients with myelodysplastic syndrome and ring sideroblasts (MDS-RS) present with symptomatic anemia due to ineffective erythropoiesis that impedes their quality of life and increases morbidity. More than 80% of patients with MDS-RS harbor splicing factor 3B subunit 1 (SF3B1) mutations, the founder aberration driving MDS-RS disease. Here, we report how mis-splicing of coenzyme A synthase (
COASY
), induced by mutations in
SF3B1
, affects heme biosynthesis and erythropoiesis. Our data revealed that
COASY
was up-regulated during normal erythroid differentiation, and its silencing prevented the formation of erythroid colonies, impeded erythroid differentiation, and precluded heme accumulation. In patients with MDS-RS, loss of protein due to
COASY
mis-splicing led to depletion of both CoA and succinyl-CoA. Supplementation with COASY substrate (vitamin B5) rescued CoA and succinyl-CoA concentrations in
SF3B1mut
cells and mended erythropoiesis differentiation defects in MDS-RS primary patient cells. Our findings reveal a key role of the COASY pathway in erythroid maturation and identify upstream and downstream metabolites of COASY as a potential treatment for anemia in patients with MDS-RS.